FABP1 and metabolic dysfunction-associated steatohepatitis: In clinical studies, the proteomic screen indicated that L‐FABP was induced in patients with simple steatosis while reduced in the progressive form of NASH (fibrosis stage 2–4) when compared to the mild form (fibrosis stage 0–1).[58] The paradoxical effect of L‐FABP in hepatic fibrogenesis and reversal from liver fibrosis as well as its protective role in in vitro HSC activation reveals its complexity in hepatic pathogenesis and distinct cell‐specific function.